BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $303,919 | -17.2% | 8,053 | 0.0% | 0.03% | -9.7% |
| Q2 2023 | $366,896 | +8.6% | 8,053 | -3.3% | 0.03% | +3.3% |
| Q1 2023 | $337,785 | -20.4% | 8,328 | 0.0% | 0.03% | -26.8% |
| Q4 2022 | $424,480 | -9.3% | 8,328 | -4.1% | 0.04% | -21.2% |
| Q3 2022 | $468,000 | -16.7% | 8,686 | -0.8% | 0.05% | -8.8% |
| Q2 2022 | $562,000 | -17.1% | 8,754 | 0.0% | 0.06% | -1.7% |
| Q1 2022 | $678,000 | -22.3% | 8,754 | -14.0% | 0.06% | -21.6% |
| Q4 2021 | $873,000 | +6.6% | 10,179 | 0.0% | 0.07% | -6.3% |
| Q3 2021 | $819,000 | -1.7% | 10,179 | -1.6% | 0.08% | -4.8% |
| Q2 2021 | $833,000 | +2.8% | 10,347 | +7.7% | 0.08% | -9.8% |
| Q1 2021 | $810,000 | +5.1% | 9,606 | 0.0% | 0.09% | -8.0% |
| Q4 2020 | $771,000 | -0.1% | 9,606 | 0.0% | 0.10% | -20.0% |
| Q3 2020 | $772,000 | -6.8% | 9,606 | 0.0% | 0.12% | -16.1% |
| Q2 2020 | $828,000 | +6.2% | 9,606 | 0.0% | 0.15% | -18.6% |
| Q1 2020 | $780,000 | -6.4% | 9,606 | 0.0% | 0.18% | +25.3% |
| Q4 2019 | $833,000 | -1.0% | 9,606 | -0.1% | 0.15% | -10.4% |
| Q3 2019 | $841,000 | -27.0% | 9,615 | -31.6% | 0.16% | -25.9% |
| Q2 2019 | $1,152,000 | +3.7% | 14,065 | +2.9% | 0.22% | -3.5% |
| Q1 2019 | $1,111,000 | +23.4% | 13,670 | 0.0% | 0.23% | +11.2% |
| Q4 2018 | $900,000 | -16.1% | 13,670 | -1.8% | 0.20% | -4.7% |
| Q3 2018 | $1,073,000 | -2.3% | 13,920 | -6.4% | 0.22% | -5.7% |
| Q2 2018 | $1,098,000 | +3.1% | 14,870 | -2.9% | 0.23% | -10.2% |
| Q1 2018 | $1,065,000 | +1.9% | 15,320 | -3.9% | 0.25% | +3.3% |
| Q4 2017 | $1,045,000 | -7.2% | 15,950 | -12.1% | 0.25% | -14.9% |
| Q3 2017 | $1,126,000 | +2.6% | 18,150 | 0.0% | 0.29% | -4.0% |
| Q2 2017 | $1,098,000 | +16.1% | 18,150 | -0.5% | 0.30% | +9.9% |
| Q1 2017 | $946,000 | +7.4% | 18,250 | -8.1% | 0.27% | -5.5% |
| Q4 2016 | $881,000 | -2.9% | 19,860 | +4.2% | 0.29% | -7.6% |
| Q3 2016 | $907,000 | -12.5% | 19,060 | -20.6% | 0.31% | -19.1% |
| Q2 2016 | $1,036,000 | +5.1% | 24,010 | 0.0% | 0.39% | -1.5% |
| Q1 2016 | $986,000 | +7.6% | 24,010 | 0.0% | 0.39% | +3.4% |
| Q4 2015 | $916,000 | +545.1% | 24,010 | +454.5% | 0.38% | +408.0% |
| Q3 2015 | $142,000 | -18.4% | 4,330 | 0.0% | 0.08% | -8.5% |
| Q2 2015 | $174,000 | -41.6% | 4,330 | 0.0% | 0.08% | -40.6% |
| Q1 2015 | $298,000 | -6.0% | 4,330 | 0.0% | 0.14% | -15.9% |
| Q4 2014 | $317,000 | +217.0% | 4,330 | +225.6% | 0.16% | +178.0% |
| Q3 2014 | $100,000 | +4.2% | 1,330 | 0.0% | 0.06% | +1.7% |
| Q2 2014 | $96,000 | -2.0% | 1,330 | 0.0% | 0.06% | -9.4% |
| Q1 2014 | $98,000 | +6.5% | 1,330 | 0.0% | 0.06% | -1.5% |
| Q4 2013 | $92,000 | – | 1,330 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |